vs
Side-by-side financial comparison of A2Z CUST2MATE SOLUTIONS CORP. (AZ) and Prime Medicine, Inc. (PRME). Click either name above to swap in a different company.
A2Z CUST2MATE SOLUTIONS CORP. is the larger business by last-quarter revenue ($1.5M vs $838.0K, roughly 1.8× Prime Medicine, Inc.). A2Z CUST2MATE SOLUTIONS CORP. runs the higher net margin — -90.4% vs -5498.7%, a 5408.3% gap on every dollar of revenue. On growth, A2Z CUST2MATE SOLUTIONS CORP. posted the faster year-over-year revenue change (-1.6% vs -61.6%).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
AZ vs PRME — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5M | $838.0K |
| Net Profit | $-1.4M | $-46.1M |
| Gross Margin | 34.0% | — |
| Operating Margin | -265.9% | -5800.5% |
| Net Margin | -90.4% | -5498.7% |
| Revenue YoY | -1.6% | -61.6% |
| Net Profit YoY | 60.4% | -9.0% |
| EPS (diluted) | — | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $838.0K | ||
| Q3 25 | $1.5M | $1.2M | ||
| Q2 25 | $1.2M | $1.1M | ||
| Q1 25 | $2.0M | $1.5M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $1.6M | — | ||
| Q2 24 | $1.1M | $0 | ||
| Q1 24 | — | $591.0K |
| Q4 25 | — | $-46.1M | ||
| Q3 25 | $-1.4M | $-50.6M | ||
| Q2 25 | $-12.6M | $-52.6M | ||
| Q1 25 | $-6.8M | $-51.9M | ||
| Q4 24 | — | $-42.3M | ||
| Q3 24 | $-3.5M | — | ||
| Q2 24 | $-3.2M | $-55.3M | ||
| Q1 24 | — | $-45.8M |
| Q4 25 | — | — | ||
| Q3 25 | 34.0% | — | ||
| Q2 25 | 23.3% | — | ||
| Q1 25 | 31.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 43.9% | — | ||
| Q2 24 | 7.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -5800.5% | ||
| Q3 25 | -265.9% | -4406.0% | ||
| Q2 25 | -585.9% | -4787.2% | ||
| Q1 25 | -381.4% | -3603.3% | ||
| Q4 24 | — | -2025.7% | ||
| Q3 24 | -167.0% | — | ||
| Q2 24 | -272.1% | — | ||
| Q1 24 | — | -8179.5% |
| Q4 25 | — | -5498.7% | ||
| Q3 25 | -90.4% | -4129.1% | ||
| Q2 25 | -1085.4% | -4716.7% | ||
| Q1 25 | -342.1% | -3568.8% | ||
| Q4 24 | — | -1936.6% | ||
| Q3 24 | -224.7% | — | ||
| Q2 24 | -277.4% | — | ||
| Q1 24 | — | -7743.0% |
| Q4 25 | — | $-0.22 | ||
| Q3 25 | — | $-0.32 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | $-0.19 | $-0.40 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.05 | $-0.46 | ||
| Q1 24 | — | $-0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $43.2M | $63.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $71.3M | $120.9M |
| Total Assets | $81.9M | $342.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $63.0M | ||
| Q3 25 | $43.2M | $71.4M | ||
| Q2 25 | $28.5M | $53.8M | ||
| Q1 25 | $24.2M | $91.9M | ||
| Q4 24 | — | $182.5M | ||
| Q3 24 | $3.4M | — | ||
| Q2 24 | $653.0K | $55.6M | ||
| Q1 24 | — | $94.2M |
| Q4 25 | — | $120.9M | ||
| Q3 25 | $71.3M | $161.8M | ||
| Q2 25 | $31.5M | $60.9M | ||
| Q1 25 | $31.3M | $106.9M | ||
| Q4 24 | — | $153.1M | ||
| Q3 24 | $-504.0K | — | ||
| Q2 24 | $-340.0K | $196.6M | ||
| Q1 24 | — | $243.8M |
| Q4 25 | — | $342.7M | ||
| Q3 25 | $81.9M | $385.0M | ||
| Q2 25 | $46.1M | $279.0M | ||
| Q1 25 | $42.2M | $328.2M | ||
| Q4 24 | — | $297.5M | ||
| Q3 24 | $10.2M | — | ||
| Q2 24 | $7.2M | $259.7M | ||
| Q1 24 | — | $311.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.0M | $-37.3M |
| Free Cash FlowOCF − Capex | — | $-37.5M |
| FCF MarginFCF / Revenue | — | -4480.4% |
| Capex IntensityCapex / Revenue | — | 34.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-167.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-37.3M | ||
| Q3 25 | $-4.0M | $-35.0M | ||
| Q2 25 | $-5.9M | $-41.4M | ||
| Q1 25 | $-3.8M | $-48.9M | ||
| Q4 24 | — | $16.2M | ||
| Q3 24 | $-658.0K | — | ||
| Q2 24 | $-3.7M | $-45.5M | ||
| Q1 24 | — | $-67.7M |
| Q4 25 | — | $-37.5M | ||
| Q3 25 | — | $-35.3M | ||
| Q2 25 | — | $-43.0M | ||
| Q1 25 | — | $-51.3M | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-47.4M | ||
| Q1 24 | — | $-70.0M |
| Q4 25 | — | -4480.4% | ||
| Q3 25 | — | -2880.5% | ||
| Q2 25 | — | -3855.1% | ||
| Q1 25 | — | -3526.8% | ||
| Q4 24 | — | 662.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -11849.6% |
| Q4 25 | — | 34.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 141.0% | ||
| Q1 25 | — | 166.6% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 393.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
